33.38

0.33% 0.05

Royalty Pharma Plc (RPRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Storia dei dividendi

Precedente Chiudi:

$33.33

Aprire:

$33.29

Volume 24 ore:

316.75K

Relative Volume:

0.09

Capitalizzazione di mercato:

$14.44B

Reddito:

$2.27B

Utile/perdita netta:

$1.15B

Rapporto P/E:

13.09

EPS:

2.55

Flusso di cassa netto:

$2.80B

1 W Prestazione:

+3.34%

1M Prestazione:

+10.36%

6M Prestazione:

+21.16%

1 anno Prestazione:

+7.08%

Intervallo 1D:

$33.06

$33.67

Intervallo di 1 settimana:

$32.00

$33.69

Portata 52W:

$24.05

$33.69

Royalty Pharma Plc Stock (RPRX) Company Profile

Nome

Royalty Pharma Plc

Settore

Healthcare (1174)

Industria

Biotechnology (677)

Telefono

(212) 883-0200

Indirizzo

110 EAST 59TH STREET, NEW YORK, NY

Dipendente

Cinguettio

Prossima data di guadagno

2025-02-11

Ultimi documenti SEC

RPRX's Discussions on Twitter

Confronta RPRX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RPRX Royalty Pharma Plc	33.41	14.44B	2.27B	1.15B	2.80B	2.55
VRTX Vertex Pharmaceuticals Inc	480.80	123.34B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	696.74	76.09B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	647.78	39.34B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.98	32.49B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	117.24	28.26B	3.30B	-501.07M	1.03B	-2.1146

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-06-03	Downgrade	UBS	Buy → Neutral
2022-06-14	Ripresa	UBS	Buy
2022-05-13	Iniziato	Scotiabank	Sector Outperform
2022-04-27	Iniziato	Goldman	Buy
2022-04-14	Aggiornamento	JP Morgan	Neutral → Overweight
2022-04-06	Ripresa	Morgan Stanley	Overweight
2021-10-29	Aggiornamento	Citigroup	Neutral → Buy
2021-07-30	Iniziato	Tigress Financial	Buy
2020-11-09	Aggiornamento	UBS	Neutral → Buy
2020-07-14	Iniziato	Evercore ISI	In-line
2020-07-13	Iniziato	BofA Securities	Buy
2020-07-13	Iniziato	Citigroup	Neutral
2020-07-13	Iniziato	Cowen	Outperform
2020-07-13	Iniziato	Goldman	Neutral
2020-07-13	Iniziato	JP Morgan	Neutral
2020-07-13	Iniziato	Morgan Stanley	Equal-Weight
2020-07-13	Iniziato	SunTrust	Buy
2020-07-13	Iniziato	UBS	Neutral

Mostra tutto

Royalty Pharma Plc Borsa (RPRX) Ultime notizie

Feb 20, 2025

Baillie Gifford & Co. Sells 1,987,975 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 20, 2025

Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighWhat's Next? - MarketBeat

Feb 20, 2025

Van ECK Associates Corp Increases Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 20, 2025

Feb 19, 2025

Ex-Dividend Reminder: Royalty Pharma, Piedmont Office Realty Trust and Western Asset Diversified Income - Nasdaq

Feb 19, 2025

(RPRX) Trading Signals - Stock Traders Daily

Feb 19, 2025

Feb 18, 2025

Allspring Global Investments Holdings LLC Boosts Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 18, 2025

Feb 16, 2025

Royalty Pharma (RPRX) to Release Quarterly Earnings on Thursday - MarketBeat

Feb 16, 2025

Feb 15, 2025

Sumitomo Mitsui Trust Group Inc. Reduces Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 15, 2025

abrdn plc Sells 14,685 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Feb 15, 2025

Royalty Pharma (NASDAQ:RPRX) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat

Feb 15, 2025

Feb 14, 2025

Royalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 Transition - MSN

Feb 14, 2025

Feb 13, 2025

Royalty Pharma's Strong Portfolio Growth and Manager Acquisition Boost Long-Term Outlook - Morningstar

Feb 13, 2025

Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts - MSN

Feb 13, 2025

Dechert advises Royalty Pharma on lupus drug funding - ICLG.com

Feb 13, 2025

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Lecap Asset Management Ltd. - MarketBeat

Feb 13, 2025

Royalty Pharma announces R&D funding collaboration with Biogen - TipRanks

Feb 13, 2025

Feb 12, 2025

Royalty Pharma: Delivering Growth With A Positive Story Ahead (NASDAQ:RPRX) - Seeking Alpha

Feb 12, 2025

Royalty Pharma Earnings: Solid Growth; Diverse Portfolio Supports Positive Long-Term Outlook - Morningstar

Feb 12, 2025